Welcome to our dedicated page for Radiopharm Theranostics American Depositary Shares news (Ticker: RADX), a resource for investors and traders seeking the latest updates and insights on Radiopharm Theranostics American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Radiopharm Theranostics American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Radiopharm Theranostics American Depositary Shares's position in the market.
Radiopharm Theranostics announces the listing of its American Depositary Shares (ADSs) on the Nasdaq Capital Market under the ticker symbol RADX, effective November 27, 2024. Each ADS represents 300 ordinary shares, complementing the company's primary ASX listing. The Nasdaq listing was achieved without an associated capital raise, with Deutsche Bank Trust Company Americas appointed as depositary. Currently, 21% of Radiopharm's shareholders are US-based. The company expects initial trading volume may be as existing shareholders convert ordinary shares to ADSs.
FAQ
What is the current stock price of Radiopharm Theranostics American Depositary Shares (RADX)?
